JCJordi Camps

Jordi Camps

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jordi Camps has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    Supplementary Figure S1-4 and Supplementary Table S1-3

  • Open Access

    Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    The development of single-cell RNA sequencing (scRNA-seq) technologies has greatly contributed to deciphering the tumor microenvironment (TME). An enormous amount of independent scRNA-seq studies have been published representing a valuable resource that provides opportunities for meta-analysis studies. However, the massive amount of biological information, the marked heterogeneity and variability between studies, and the technical challenges in processing heterogeneous datasets create major bottlenecks for the full exploitation of scRNA-seq data. We have developed IMMUcan scDB (https://immucanscdb.vital-it.ch), a fully integrated scRNA-seq database exclusively dedicated to human cancer and accessible to nonspecialists. IMMUcan scDB encompasses 144 datasets on 56 different cancer types, annotated in 50 fields containing precise clinical, technological, and biological information. A data processing pipeline was developed and organized in four steps: (i) data collection; (ii) data processing (quality control and sample integration); (iii) supervised cell annotation with a cell ontology classifier of the TME; and (iv) interface to analyze TME in a cancer type–specific or global manner. This framework was used to explore datasets across tumor locations in a gene-centric (CXCL13) and cell-centric (B cells) manner as well as to conduct meta-analysis studies such as ranking immune cell types and genes correlated to malignant transformation. This integrated, freely accessible, and user-friendly resource represents an unprecedented level of detailed annotation, offering vast possibilities for downstream exploitation of human cancer scRNA-seq data for discovery and validation studies.Significance:The IMMUcan scDB database is an accessible supportive tool to analyze and decipher tumor-associated single-cell RNA sequencing data, allowing researchers to maximally use this data to provide new insights into cancer biology.

  • Open Access

    Supplementary Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    Supplementary Figure S1-4 and Supplementary Table S1-3

  • Open Access

    Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    The development of single-cell RNA sequencing (scRNA-seq) technologies has greatly contributed to deciphering the tumor microenvironment (TME). An enormous amount of independent scRNA-seq studies have been published representing a valuable resource that provides opportunities for meta-analysis studies. However, the massive amount of biological information, the marked heterogeneity and variability between studies, and the technical challenges in processing heterogeneous datasets create major bottlenecks for the full exploitation of scRNA-seq data. We have developed IMMUcan scDB (https://immucanscdb.vital-it.ch), a fully integrated scRNA-seq database exclusively dedicated to human cancer and accessible to nonspecialists. IMMUcan scDB encompasses 144 datasets on 56 different cancer types, annotated in 50 fields containing precise clinical, technological, and biological information. A data processing pipeline was developed and organized in four steps: (i) data collection; (ii) data processing (quality control and sample integration); (iii) supervised cell annotation with a cell ontology classifier of the TME; and (iv) interface to analyze TME in a cancer type–specific or global manner. This framework was used to explore datasets across tumor locations in a gene-centric (CXCL13) and cell-centric (B cells) manner as well as to conduct meta-analysis studies such as ranking immune cell types and genes correlated to malignant transformation. This integrated, freely accessible, and user-friendly resource represents an unprecedented level of detailed annotation, offering vast possibilities for downstream exploitation of human cancer scRNA-seq data for discovery and validation studies.Significance:The IMMUcan scDB database is an accessible supportive tool to analyze and decipher tumor-associated single-cell RNA sequencing data, allowing researchers to maximally use this data to provide new insights into cancer biology.

  • Open Access

    Supplementary Data from Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    Supplementary Figure S1-4 and Supplementary Table S1-3

  • Open Access

    Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database

    by Jordi Camps, Floriane Noël, Robin Liechti, Lucile Massenet-Regad, Sidwell Rigade, Lou Götz, Caroline Hoffmann, Elise Amblard, Melissa Saichi, Mahmoud M. Ibrahim, et al.

    The development of single-cell RNA sequencing (scRNA-seq) technologies has greatly contributed to deciphering the tumor microenvironment (TME). An enormous amount of independent scRNA-seq studies have been published representing a valuable resource that provides opportunities for meta-analysis studies. However, the massive amount of biological information, the marked heterogeneity and variability between studies, and the technical challenges in processing heterogeneous datasets create major bottlenecks for the full exploitation of scRNA-seq data. We have developed IMMUcan scDB (https://immucanscdb.vital-it.ch), a fully integrated scRNA-seq database exclusively dedicated to human cancer and accessible to nonspecialists. IMMUcan scDB encompasses 144 datasets on 56 different cancer types, annotated in 50 fields containing precise clinical, technological, and biological information. A data processing pipeline was developed and organized in four steps: (i) data collection; (ii) data processing (quality control and sample integration); (iii) supervised cell annotation with a cell ontology classifier of the TME; and (iv) interface to analyze TME in a cancer type–specific or global manner. This framework was used to explore datasets across tumor locations in a gene-centric (CXCL13) and cell-centric (B cells) manner as well as to conduct meta-analysis studies such as ranking immune cell types and genes correlated to malignant transformation. This integrated, freely accessible, and user-friendly resource represents an unprecedented level of detailed annotation, offering vast possibilities for downstream exploitation of human cancer scRNA-seq data for discovery and validation studies. Significance: The IMMUcan scDB database is an accessible supportive tool to analyze and decipher tumor-associated single-cell RNA sequencing data, allowing researchers to maximally use this data to provide new insights into cancer biology.


  • Tissue damage induces a conserved stress response that initiates quiescent muscle stem cell activation

    by Léo Machado, Perla Geara, Jordi Camps, Matthieu Dos Santos, Fatima Teixeira-Clerc, Jens Van Herck, Hugo Varet, Rachel Legendre, Jean-Michel Pawlotsky, Maurilio Sampaolesi, et al.


  • Open Access

    Growth Factor Screening in Dystrophic Muscles Reveals PDGFB/PDGFRB-Mediated Migration of Interstitial Stem Cells

    by Jordi Camps, Hanne Grosemans, Rik Gijsbers, Christa Maes, Maurilio Sampaolesi

    Progressive muscle degeneration followed by dilated cardiomyopathy is a hallmark of muscular dystrophy. Stem cell therapy is suggested to replace diseased myofibers by healthy myofibers, although so far, we are faced by low efficiencies of migration and engraftment of stem cells. Chemokines are signalling proteins guiding cell migration and have been shown to tightly regulate muscle tissue repair. We sought to determine which chemokines are expressed in dystrophic muscles undergoing tissue remodelling. Therefore, we analysed the expression of chemokines and chemokine receptors in skeletal and cardiac muscles from Sarcoglycan-α null, Sarcoglycan-β null and immunodeficient Sgcβ-null mice. We found that several chemokines are dysregulated in dystrophic muscles. We further show that one of these, platelet-derived growth factor-B, promotes interstitial stem cell migration. This finding provides perspective to an approachable mechanism for improving stem cell homing towards dystrophic muscles.